A phase3 study measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese subjects with subclinical atherosclerosis

Trial Identifier: D3565C00003
Sponsor: AstraZeneca
NCTID:: NCT02546323
Start Date: September 2015
Primary Completion Date: January 2019
Study Completion Date: January 2019
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China beijing, China, 100191
China Beijing, China, 100050
China Beijing, China, 100035
China Beijing, China, 100853
China Bengbu, China, 233060
China Changsha, China, 410011
China Chongqin, China, 400042
China guangzhou, China, 510260
China Guangzhou, China, 510630
China Guangzhou, China, 510120
China Guangzhou, China, 510080
China Guangzhou, China, 510515
China Haerbin, China, 150001
China Nanchang, China, 330006
China Nanjing, China, 210009
China Ningbo, China, 315010
China Shanghai, China, 200032
China Shanghai, China, 200065
China Shanghai, China, 200090
China Shenyang, China, 110001
China Tianjin, China, 300457
China Wenzhou, China, CN-325000
China Wuhan, China, 430022
China Xian, China, 710061